Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLIMMER: CHF 5259 dose-ranging in COPD
NCT03084796Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jul 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glycopyrronium bromide in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Started Jul 2017; status: completed.
02
Drugs
glycopyrronium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03084796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03084796.